Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of COR-2003 and COR-1004 in Healthy Individuals
NCT07858019Phase 1Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Aug 2027
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of COR-2003 in hypertension (HTN) and hypercholesterolemia (4 arms). Primary endpoint: Adverse Events at 12 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
COR-2003
03
Conditions
hypertension (HTN)hypercholesterolemia
Beyond the preview
Go deeper on NCT07858019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07858019.